Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.1K
Overview
51.1K
Cancer Vaccines01:30

Cancer Vaccines

917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Immunological Memory01:23

Immunological Memory

14.9K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR.

GeroScience·2026
Same author

Scalable long-read nanopore HPV16 amplicon-based whole-genome sequencing.

Scientific reports·2025
Same author

Cervical HPV 18 detection is associated with high-grade cervical dysplasia in Kenyan and Ugandan women living with HIV.

Gynecologic oncology reports·2025
Same author

Associations of the Colon Tissue Microbiome and Circulating Bile Acids With Colorectal Adenoma Among Average-Risk Women.

Cancer medicine·2025
Same author

Response to Hanif and Sholihah.

Journal of the National Cancer Institute·2025
Same author

Validation of TypeSeq2, a Next-Generation-Based Sequencing Assay for the Detection of 46 Human Papillomavirus Genotypes, at the US National Cancer Institute and Costa Rica Laboratories.

The Journal of infectious diseases·2025

Related Experiment Video

Updated: Jan 6, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.1K

Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction.

Aislinn DeSieghardt1, Lili Ding1,2, Aaron Ermel3

  • 1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

JAMA Pediatrics
|September 29, 2025
PubMed
Summary
This summary is machine-generated.

The human papillomavirus (HPV) vaccine demonstrates robust effectiveness and herd protection 17 years post-introduction, even in high-risk young women. This supports ongoing vaccination and cancer prevention strategies.

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.4K

Related Experiment Videos

Last Updated: Jan 6, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.1K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

22.4K

Area of Science:

  • Immunology
  • Public Health
  • Oncology

Background:

  • Clinical trials show high HPV vaccine efficacy, but real-world population-level data are needed for policy.
  • Effectiveness in high-risk adolescent girls and young women, especially after 9-valent HPV vaccine (9vHPV) introduction, is not well understood.

Purpose of the Study:

  • To assess the effectiveness and herd protection of HPV vaccines over 17 years.
  • To evaluate vaccine impact in adolescent girls and young women at increased risk for HPV infection and related cancers.

Main Methods:

  • Cross-sectional analysis of 6 surveillance studies (2006-2023) involving sexually experienced females aged 13-26.
  • Comparison of HPV type prevalence between vaccinated and unvaccinated participants, using propensity score weighting to adjust for confounders.
  • Assessment of 2-valent (2vHPV), 4-valent (4vHPV), and 9vHPV vaccine effectiveness.

Main Results:

  • Vaccination rates increased significantly from 2006 to 2023 (0% to 82.1%).
  • Among vaccinated participants, HPV positivity decreased substantially across all vaccine types (e.g., 98.4% for 2vHPV, 94.2% for 4vHPV, 75.7% for 9vHPV).
  • Significant reductions in HPV odds were observed for all participants, vaccinated, and unvaccinated groups, particularly for 2vHPV and 4vHPV.

Conclusions:

  • HPV vaccination provides robust population-level effectiveness and herd protection 17 years after introduction.
  • These findings support HPV vaccination for cancer prevention, even in populations with higher HPV risk or incomplete vaccination.
  • The study highlights the long-term public health benefits of HPV vaccination programs.